1. Home
  2. GOSS vs XLO Comparison

GOSS vs XLO Comparison

Compare GOSS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$10.56

Market Cap

65.6M

Sector

Health Care

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$8.96

Market Cap

56.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOSS
XLO
Founded
2015
2016
Country
United States
United States
Employees
162
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.6M
56.9M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
GOSS
XLO
Price
$10.56
$8.96
Analyst Decision
Buy
Buy
Analyst Count
8
1
Target Price
$4.19
$28.00
AVG Volume (30 Days)
8.2M
8.9K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$48,471,000.00
$43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$201.64
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
589.88
52 Week Low
$0.11
$0.46
52 Week High
$12.52
$9.90

Technical Indicators

Market Signals
Indicator
GOSS
XLO
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
GOSS
XLO

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: